Schema

Arm A
TAK-228 3mg po daily continuously

Accrual: 40 patients
Cycle: 28 days

1. Treatment will continue until progression or unacceptable toxicity.
2. Patients will be followed for response until progression, even if non-protocol therapy is initiated, and for survival for 5 years from the date of registration.